Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$24.42
+0.05 (+0.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-70.6M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.7%
↓Gross Margin
26.4%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.6%
FCF CAGR
—
FCF margin
-18.7%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $378.3M · net income $-69.7M · FCF $-70.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $378.3M | $378.3M | $421.7M | $835.5M | $784.7M |
| Net Income | $-69.7M | $-69.7M | $-19.9M | $243.1M | $286.5M |
| EBITDA | $-6.0M | $-6.0M | $20.0M | $363.5M | $369.2M |
| EPS | -0.55 | -0.55 | -0.16 | 1.93 | 2.27 |
| Gross Margin | 26.4% | 26.4% | 29.9% | 57.9% | 60.1% |
| Operating Margin | -12.6% | -12.6% | -3.3% | 39.1% | 41.4% |
| Net Margin | -18.4% | -18.4% | -4.7% | 29.1% | 36.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | — | 0.03 |
| Current Ratio | 4.11 | 4.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-70.6M | $-70.6M | $18.8M | $-158.3M | $120.5M |
| Returns | |||||
| ROE | -4.7% | -4.7% | -1.3% | 15.2% | 20.8% |
| Valuation | |||||
| P/E | — | — | — | 29.17 | 32.92 |
| EV/EBITDA | — | — | 170.48 | 19.10 | 24.82 |
| P/B | 2.08 | 2.08 | 2.24 | 4.42 | 6.85 |
| Growth & Yield | |||||
| Revenue Growth | -10.3% | -10.3% | -49.5% | 6.5% | — |
| EPS Growth | -243.8% | -243.8% | -108.3% | -15.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.55
Residual
-36.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.